Publications by authors named "E Corrada"
Article Synopsis
- * A systematic review including 68,653 patients found that GLP1-ra significantly reduced heart failure hospitalizations and cardiovascular deaths only in patients without previous HF history.
- * Despite the lack of benefits in HF patients regarding hospitalizations and deaths, GLP1-ra were effective in reducing major adverse cardiovascular events (MACE) for both groups without significant differences in treatment effect based on HF history.
Article Synopsis
- The analysis from the Altshock-2 registry aimed to compare the clinical features and management of cardiogenic shock due to acutely decompensated heart failure (ADHF-CS) versus that caused by acute myocardial infarction (AMI-CS).
- It found that patients with ADHF-CS were younger but had worse kidney and liver function, leading to longer hospital stays and increased use of heart replacement therapies.
- In terms of treatment, norepinephrine was more common for AMI-CS, while epinephrine was more frequently used for ADHF-CS, and overall in-hospital mortality rates were similar between the two groups.
Background: Cardiogenic shock (CS) includes several phenotypes with heterogenous hemodynamic features. Timely prognostication is warranted to identify patients requiring treatment escalation. We explored the association of the updated Society for Cardiovascular Angiography and Interventions (SCAI) stages classification with in-hospital mortality using a prospective national registry.
View Article and Find Full Text PDFUnlabelled: Hemoglobin (Hb) levels have emerged as a useful tool for risk stratification and the prediction of outcome after myocardial infarction. We aimed at evaluating the prognostic impact of this parameter among patients in advanced age, where the larger prevalence of anemia and the higher rate of comorbidities could directly impact on the cardiovascular risk.
Methods: All the patients in the ELDERLY-2 trial, were included in this analysis and stratified according to the values of hemoglobin at admission.